Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in sarcoma and GIST
- Trial result
Sarcoma and GIST
Nivolumab + cabozantinib shows feasible safety and prolonged disease stabilization in a small HIV-positive solid-tumor cohort
Nivolumab is a PD-1 immune checkpoint inhibitor and cabozantinib is a multi-kinase TKI (including VEGFR2/MET/AXL) with putative myeloid/TME-modulating effects; this multicenter Phase 1 pilot enrolled people with HIV…
NCT04514484 - New trial
Sarcoma and GIST
Phase 2 LX-101 IGF-1R–targeted methotrexate conjugate in R/R Ewing sarcoma/DSRCT
MD Anderson’s RAPID platform is an open-label, Bayesian, multi-center Phase 2 study designed to quickly screen “promising drugs” and combinations for adolescent and young adult patients with relapsed/refractory Ewing…
NCT07781891 Exploratory - Trial result
Sarcoma and GIST
Vimseltinib (CSF1R switch-control inhibitor) delivers 64% ORR in surgery-ineligible TGCT, including post–CSF1/CSF1R-treated patients
Vimseltinib is an oral “switch-control” kinase inhibitor of CSF1R designed to blunt the CSF1-driven macrophage biology underlying tenosynovial giant cell tumor (TGCT). In the multicenter, open-label Phase 2 expansion…
NCT03069469 - New trial
Sarcoma and GIST
Phase 1/2 domatinostat class I HDAC inhibitor + sirolimus mTOR inhibitor in R/R sarcoma/osteosarcoma.
This multicenter, open-label, cohort-sequential Phase 1/2 trial tests domatinostat plus sirolimus in adolescents and adults with relapsed/refractory sarcoma (Phase 1 dose escalation) and relapsed/refractory…
NCT07725380 Exploratory - Trial result
Sarcoma and GIST
Brigimadlin (MDM2–p53 antagonist) Misses PFS Endpoint vs Doxorubicin in 1L DDLPS, Despite Higher ORR
Brigimadlin (BI 907828) is an oral small-molecule MDM2 inhibitor that disrupts MDM2–p53 binding to reactivate TP53 signaling, and was tested against standard first-line doxorubicin in Brightline-1 (randomized Phase…
NCT05218499 - Trial result
Sarcoma and GIST
PRAME-directed TCR-T (anzu-cel/IMA203CD8) hits 50% cORR with 12.7-mo DoR in R/R synovial sarcoma
Anzutresgene autoleucel (anzu-cel, IMA203) is an autologous PRAME-directed TCR T-cell therapy (HLA-A*02:01–restricted), while IMA203CD8 adds an engineered CD8 co-receptor to broaden tumor-cell recognition by both…
NCT03686124 - Trial result
Sarcoma and GIST
Velzatinib (IDRX-42) selective KIT inhibitor drives 61% ORR in 1L GIST; 13.7-mo mPFS in 2L
Velzatinib (IDRX-42; subject to USAN approval) is a next-gen, selective KIT inhibitor designed for broad coverage across primary KIT exons 9/11 and common secondary resistance mutations (exons 13/14 ATP-binding…
NCT05489237 - Trial result
Sarcoma and GIST
Pimicotinib (CSF1R inhibitor) sustains ~76% ORR and improves knee ROM/PF across TGCT sites
Pimicotinib is an oral, highly selective CSF-1 receptor (CSF1R) inhibitor evaluated in the global Phase 3 MANEUVER trial (NCT05804045) in symptomatic, unresectable TGCT; this analysis reports longer-term outcomes by…
NCT05804045 - Trial result
Sarcoma and GIST
Lete-cel (NY-ESO-1 TCR-T) and afami-cel (MAGE-A4 TCR-T) show ~29–43% ORR in pediatric metastatic synovial sarcoma
Lete-cel is an engineered autologous TCR-T targeting NY-ESO-1 and afami-cel is an engineered autologous TCR-T targeting MAGE-A4; this pooled pediatric analysis across four Phase II studies (NCT01343043, NCT03967223,…
NCT01343043 - Trial result
Sarcoma and GIST
Catequentinib (AL3818) multitarget RTK inhibitor delivers 26.8% ORR with 18.3-mo mPFS in advanced ASPS (APROMISS)
Catequentinib hydrochloride (AL3818) is an oral multitargeted receptor tyrosine kinase inhibitor (anti-angiogenic TKI class) evaluated as monotherapy in the open-label, non-randomized ASPS cohort of the Phase 3…
NCT03016819 - Trial result
Sarcoma and GIST
RMS13 (NCT01871766) Response-Adapted Metastasis RT Shows Soft-Tissue “CR” Still Relapses in HR RMS
RMS13 is a Phase II prospective multicenter pediatric high-risk metastatic rhabdomyosarcoma study testing interval-compressed multiagent chemotherapy plus risk-adapted proton radiotherapy (RT) to primary tumor and…
- Trial result
Sarcoma and GIST
Pom/Nivo (IMiD + PD-1 blockade) hits 100% response in evaluable Kaposi sarcoma, with manageable neutropenia
Pomalidomide (Pom), an oral immunomodulatory drug that augments T-cell co-stimulation, was combined with nivolumab (Nivo), an anti–PD-1 antibody, in a 3+3 Phase I dose-escalation trial in advanced virus-associated…
NCT04902443 - Trial result
Sarcoma and GIST
Cetuximab (anti-EGFR mAb) delivers 8% RECIST PRs but high SD/ATR rate in advanced chordoma
Cetuximab is a chimeric monoclonal antibody that blocks EGFR signaling; in this investigator-initiated, single-center Phase 2 trial (NCT05041127), adults with unresectable locally recurrent/metastatic chordoma (mITT…
NCT05041127 - Trial result
Sarcoma and GIST
Rogaratinib (pan-FGFR1–4 inhibitor) posts 41.7% ORR and 31.0-mo PFS in advanced SDH-deficient GIST
Rogaratinib (BAY 1163877) is an oral pan–fibroblast growth factor receptor (FGFR1–4) tyrosine kinase inhibitor intended to shut down the FGF3/FGF4→FGFR1 autocrine loop thought to be epigenetically activated in…
NCT04595747 - Trial result
Sarcoma and GIST
Bezuclastinib (selective type 1 KIT TKI) + sunitinib (type 2 KIT/VEGFR TKI) halves progression risk in 2L GIST
Bezuclastinib is an oral, selective type 1 KIT tyrosine kinase inhibitor designed to cover common KIT resistance mutations and was paired with sunitinib, a type 2 TKI, to broaden inhibition across primary + secondary…
NCT05208047 - Trial result
Sarcoma and GIST
Velzatinib (IDRX-42) broad-spectrum KIT/PDGFRA TKI drives 19–44% ORR in advanced GIST (ctDNA VAF ↓>99%)
Velzatinib (IDRX-42; subject to USAN approval) is an oral tyrosine kinase inhibitor designed to cover common primary KIT mutations (exons 9/11) and resistance-associated secondary KIT mutations (exons 13/14/17/18).…
NCT05489237 - Trial result
Sarcoma and GIST
Gemcitabine + nab-sirolimus (albumin-bound mTOR inhibitor) delivers 30% ORR in advanced LMS with TSC1/2 alterations
Gemcitabine (antimetabolite chemotherapy) was combined with nab-sirolimus (nab-S; nanoparticle albumin-bound sirolimus, an IV mTORC1 inhibitor designed for higher intratumoral exposure) in an investigator-initiated,…
- Trial result
Sarcoma and GIST
Regorafenib (multi-kinase/VEGFR TKI) shows numerically longer OS in advanced sarcoma, but crossover-adjusted benefit drives the signal
Regorafenib is an oral multi-kinase inhibitor with anti-angiogenic activity (notably VEGFR) that has been studied across multiple sarcoma subtypes; this pooled OS analysis combined two randomized, double-blind,…
NCT01900743 - New trial
Sarcoma and GIST
Phase 2 autologous TIL adoptive cell therapy + IL‑2 (T‑cell expansion cytokine) in GIST
This Phase 2 study evaluates adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs)—patient-derived anti-tumor T cells expanded ex vivo—followed by aldesleukin (recombinant interleukin‑2), which drives…
NCT07647068 Exploratory - New trial
Sarcoma and GIST
Phase 2 indocyanine green (NIR fluorescent dye tracer) fluorescence-guided sarcoma surgery trial.
City of Hope Medical Center is running this randomized, parallel-assignment Phase 2 trial testing whether fluorescence-guided surgery can lower the unexpected positive margin rate versus standard sarcoma resection.…
NCT07650656 Exploratory - New trial
Sarcoma and GIST
Phase 1b REC-617 selective CDK7 inhibitor (transcription/cell-cycle kinase target) in RB1– LMS
MD Anderson Cancer Center is running this Phase 1b, single-group, open-label study to test whether REC-617—an oral small-molecule inhibitor of CDK7 (a cyclin-dependent kinase that supports transcriptional regulation…
NCT07633756 Exploratory - New trial
Sarcoma and GIST
Phase 2 eflornithine (DFMO) ornithine decarboxylase inhibitor added/maintenance in Ewing and osteosarcoma
This Phase 2, non-randomized, open-label basket study tests eflornithine (DFMO)—a small-molecule ornithine decarboxylase (ODC) inhibitor that suppresses polyamine synthesis—as concurrent therapy with multi-agent…
NCT07321912 Exploratory - Trial result
Sarcoma and GIST
Atezolizumab (PD‑L1) in ASPS shows low late toxicity beyond 2 years of exposure
Atezolizumab is an anti–PD‑L1 checkpoint inhibitor; in the Phase 2 NCT03141684 trial in unresectable/metastatic alveolar soft part sarcoma (ASPS), this AACR 2026 update focused on late safety among patients treated…
NCT03141684 - Trial result
Sarcoma and GIST
DOREMY: 36Gy preop radiotherapy (RT) in myxoid liposarcoma preserves ~97% 5-year local control with low late toxicity
Preoperative RT de-escalation to 36Gy in 18×2Gy followed by resection was tested in the prospective single-arm Phase 2 DOREMY trial in localized, translocation-confirmed myxoid liposarcoma of the trunk/extremity…
NCT02106312 - New trial
Sarcoma and GIST
Phase 2 methotrexate dihydrofolate reductase inhibitor optimizes HD‑MTX discharge in osteosarcoma.
This Phase 2, multicenter supportive-care/operations study from Wake Forest University Health Sciences (Wake Forest Baptist) tests whether patients with newly diagnosed high‑grade osteosarcoma (children, adolescents,…
NCT07560826 Exploratory - New trial
Sarcoma and GIST
Phase 2 KQB198 + imatinib tests EGFR-targeted protein degrader in 1L metastatic GIST.
This Phase 2, multicenter, open-label study sponsored by Kumquat Biosciences evaluates KQB198 plus imatinib in participants with unresectable or metastatic gastrointestinal stromal tumor (GIST) receiving first-line…
NCT07406633 Exploratory - New trial
Sarcoma and GIST
Pilot Definity (perflutren lipid microspheres) CEUS microbubble perfusion/pressure imaging in STS RT
This single-site, open-label, non-randomized pilot at Thomas Jefferson University tests whether contrast-enhanced ultrasound (CEUS) can feasibly guide radiotherapy (RT) planning and predict response in patients with…
NCT07436364 Exploratory - New trial
Sarcoma and GIST
Phase 2 BMS-986504 MTA-cooperative PRMT5 inhibitor for MTAP-deleted MPNST
This Phase 2, open-label study evaluates BMS-986504 (navlimetostat), an MTA-cooperative PRMT5 inhibitor, as monotherapy in unresectable malignant peripheral nerve sheath tumor (MPNST) with homozygous MTAP deletion.…
NCT07549022 Exploratory - Trial result
Sarcoma and GIST
Atezolizumab (PD-L1) Delivers 37-Month DoR in ASPS, with Fusion Subtype Driving Benefit
Atezolizumab (Tecentriq), an anti–PD-L1 monoclonal antibody, was given to patients with unresectable/metastatic alveolar soft part sarcoma (ASPS) in the pivotal single-arm Phase II Study ML39345 (NCT03141684; n=53)…
NCT03141684 - Trial result
Sarcoma and GIST
Metronomic gemcitabine/doxorubicin/docetaxel + PD-1 nivolumab posts 57% ORR and 9.4-mo PFS in advanced angiosarcoma
Metronomic GDD plus nivolumab is a dose-dense chemo–immunotherapy regimen combining cytotoxics (gemcitabine, doxorubicin, docetaxel) with PD-1 blockade (nivolumab), evaluated in a Phase II study in advanced…
NCT04535713
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.